en
svSuccessful production start for HyNap-Dasa in Xspray’s unique full-scale production line
STOCKHOLM – June 27, 2019. Xspray Pharma (Nasdaq First North: XSPRAY) today announced that the first of two full-scale production lines, producing the company's amorphous formulation on a commercial scale, is now installed and tested in Milan, Italy. This means that the development of the company's first product candidate HyNap-Dasa, an amorphous version of Sprycel® (dasatinib), is proceeding […]
Read moreXspray granted additional product patents in the United States for HyNap-Sora and HyNap-Nilo
STOCKHOLM – June 11, 2019. Xspray Pharma (Nasdaq First North: XSPRAY) announces that the United States Patent and Trademark Office (USPTO) has granted Xspray two new patents in the United States for its product candidates HyNap-Sora and HyNap-Nilo. The new patents are Xspray’s sixth and seventh product patents, respectively, in the United States, which is Xspray’s main market. […]
Read moreBulletin from the annual general meeting of Xspray Pharma AB (publ)
Press release Solna, 23 May 2019The following resolutions were passed at the annual general meeting (the “AGM”) of Xspray Pharma AB (publ) (“Xspray”) on May 23 2019, in Stockholm. Adoption of income statement and balance sheet for the financial year 2018 and discharge from liability The AGM resolved to adopt the income statement for the […]
Read moreXspray Pharma publishes Interim Report Q1, January-March 2019
May 16, 2019 ”Over the past year, we’ve tripled the number of employees and I’m very pleased to see that our entire team is performing high quality work with great commitment. Xspray is today a company well-equipped to take a drug all the way to a finished product.” Per Andersson, CEO Xspray Pharma AB (publ) […]
Read moreKerstin Hasselgren appointed CFO at Xspray Pharma
STOCKHOLM – May 3, 2019. Xspray Pharma (Nasdaq First North: XSPRAY) today announces that Kerstin Hasselgren has been appointed CFO of the company. Kerstin has extensive experience from working in publicly listed international companies, including positions as Vice President Finance at AstraZeneca within Global R&D and Global Operations. Most recently, Kerstin comes from a position as […]
Read moreNotice of annual general meeting of Xspray Pharma AB (publ)
The shareholders of Xspray Pharma AB (publ), Reg. No. 556649-3671, are summoned to the annual general meeting on Thursday 23 May 2019 at 11.00 CEST at Advokatfirman Vinge’s office on Stureplan 8 in Stockholm. Registration starts at 10.30 CEST. Right to attend the annual general meeting Shareholders who wish to attend the annual general meeting […]
Read moreXspray Pharma announces positive clinical data for the drug candidate HyNap-Sora
STOCKHOLM – February 18, 2019. Xspray Pharma AB today announced the results of a clinical Phase I pilot study with its HyNap-Sora drug candidate. The study examined HyNap-Sora’s bioavailability compared to the sorafenib cancer drug, currently marketed as Nexavar® for the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinoma. Both investigated HyNap compositions demonstrated […]
Read moreXspray Pharma publishes its Year-end Report, January – December 2018
”Following determined efforts, we demonstrated performance in 2018 that has brought us significantly closer to a market launch of HyNap-Dasa and have thus increased Xspray’s possibilities of building shareholder value.” Per Andersson, CEO Xspray Pharma AB (publ) Fourth quarter, October – December 2018, parent company Amounts in brackets refer to the corresponding period for the […]
Read moreXspray Pharma has carried out a directed share issue raising gross proceeds of approximately SEK 92 million
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. Press release Solna, 6 December 2018 Xspray Pharma AB (publ) (“Xspray” or the […]
Read moreXspray Pharma contemplates a directed share issue to continue development of its product portfolio
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. Press release Solna, 6 December 2018 Xspray Pharma AB (publ) (“Xspray” or the […]
Read more